In VivoBiopharma financing during the third quarter of 2024 totaled $17bn from 207 deals. Of those, 54 reached $100m or more. The follow-on public offering (FOPO) category made up the made up most (34%) of t
In VivoInvestment in health care companies in the US and Europe in 2021 reached $86.3bn, according to the latest annual investments and exits update from Silicon Valley Bank (SVB). This was a heady 64% up on
In VivoClive Dix is used to sorting out complicated challenges. He has founded and run several biotechs in his time and has a broad knowledge of the scientific and commercial landscapes of a variety of thera
ScripClive Dix is used to sorting out complicated challenges. He has founded and run several biotechs in his time and has a broad knowledge of the scientific and commercial landscapes of a variety of thera